Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

131.86 -2.19 (-1.63%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 200,058
Open 134.40
Bid (Size) 131.79 (8)
Ask (Size) 132.02 (7)
Prev. Close 134.05
Today's Range 131.28 - 134.40
52wk Range 131.28 - 270.57
Shares Outstanding 1,211,067,023
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Week In Review: AriBio Sells China Rights To Alzheimer’s Candidate In $770 Million Deal
South Korea’s AriBio out-licensed China rights for AR1001, an Alzheimer’s disease candidate, in an agreement worth up to $770 million. The company acquiring the asset asked to remain anonymous because... 
Via Talk Markets
4 Analysts Assess BeiGene: What You Need To Know
Via Benzinga

Performance

YTD
-25.50%
-25.50%
1 Month
-21.74%
-21.74%
3 Month
-21.42%
-21.42%
6 Month
-21.30%
-21.30%
1 Year
-50.57%
-50.57%

More News

Read More
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
Via Talk Markets
Lululemon Issues Weak Outlook, Joins Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer
Via Benzinga
Exposures Product Safety
BeiGene Ltd. (NASDAQ: BGNE) is a Leading Gainer in 3/13 Morning Trading
Via Investor Brand Network
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
From BeiGene, Ltd.
Via Business Wire
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
From BeiGene
Via Business Wire
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
Via Benzinga
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer
Via Benzinga
Exposures Product Safety
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
From BeiGene, Ltd.
Via Business Wire
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present at Upcoming Investor Conferences
From BeiGene, Ltd.
Via Business Wire
BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
From BeiGene, Ltd.
Via Business Wire
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
From BeiGene, Ltd.
Via Business Wire
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
From BeiGene, Ltd.
Via Business Wire
Hang Seng Index Set For Global Expansion With Prada, XPeng, And BeiGene On The Horizon
Via Benzinga
Get Rich Quick With These 3 Biotech Stocks to Buy Now
Via InvestorPlace
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
Via InvestorPlace
JP Morgan's Bullish View On This Chinese Biotech, Says Pullback Creates Entry Point
Via Benzinga
BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
From BeiGene, Ltd.
Via Business Wire
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
Via The Motley Fool
As China's Population Declines In 2023, Will Aging Demographics Boost Healthcare Stocks?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.